重组人生长激素治疗青春后期特发性矮小临床观察

金薇; 陈继男; 文革生; 高毅

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

x 关闭永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

重组人生长激素治疗青春后期特发性矮小临床观察

金薇, 陈继男, 文革生, 高毅

文章导航 > 药学实践与服务 > 2012 > 30(4): 293-295

金薇, 陈继男, 文革生, 高毅. 重组人生长激素治疗青春后期特发性矮小临床观察[J]. 药学实践与服务, 2012, 30(4): 293-295.

引用本文:

金薇, 陈继男, 文革生, 高毅. 重组人生长激素治疗青春后期特发性矮小临床观察[J]. 药学实践与服务, 2012, 30(4): 293-295.

JIN Wei, CHEN Ji-nan, WEN Ge-sheng, GAO Yi. Effect of recombinant human growth hormone therapy on late puberty children with idiopathic short stature[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(4): 293-295.

Citation:

JIN Wei, CHEN Ji-nan, WEN Ge-sheng, GAO Yi. Effect of recombinant human growth hormone therapy on late puberty children with idiopathic short stature[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(4): 293-295.

重组人生长激素治疗青春后期特发性矮小临床观察

浙江省湖州市妇幼保健院儿科, 浙江湖州313000

Effect of recombinant human growth hormone therapy on late puberty children with idiopathic short stature

Department of Peadiatrics, Maternal and Child Care Service Center of Huzhou, Huzhou 313000, China

摘要: 目的探讨基因重组人生长激素(rhGH)对青春后期特发性矮小的促生长效应.方法 11例青春后期矮小患儿,按性别分为2组,A组,男5例,骨龄14～15岁,B组,女6例,骨龄12.5～13.5岁,每晚睡前皮下注射rhGH,剂量0.15 IU/(kg.d),疗程6个月.结果 2组患儿的身高分别由治疗前(148.6±2.6)cm、(139.6±2.9)cm增加到(153.6±2.1)cm、(143.8±2.5)cm,生长速率分别由治疗前(3.8±0.5)cm/年、
- 特发性矮小 /
- 重组人生长激素 /
- 青春后期 /
- 骨龄
Abstract: Objective To assess the efficacy of recombinant human growth hormone (rhGH) therapy in late puberty children with idiopathic short stature. Methods 11 children in late puberty with idiopathic short stature (ISS) were divided into 2 groups according to sex.A group consisted of 5 boys, B group was composed of 6 girls. Bone age (BA) of A group was (14～15) years, and BA of B group was (12.5～13.5) years.The enrolled children were treated with subcutaneous injection of rhGH (0.15 IU/kg·d) daily before sleep for six months,and the growth velocities (GV) and the predicted adult height (PAH) before and after treatment were compared. Results The mean height of A group and B group increased from (148.6±2.6) cm and (139.6±2.9) cm to (153.6±2.1) cm and (143.8±2.5) cm respectively. The growth velocity of A group and B group increased from (3.8±0.5) cm and (3.3±0.6) cm per year to (9.8±1.7) cm and (8.4±1.8) cm per year.PAH of A group and B group increased from (158.9±3.0) cm and (147.6±1.2) cm to (160.3±3.0) cm and (149.2±1.6) cm. There was a significant increase in rhGH therapy (all P<0.05), but no change in BA during the whole course of rhGH therapy. Conclusion rhGH was an effective and safe drug in promoring the growth in late puberty children with ISS.
- idiopathic short stature /
- recombinant human growth hormone /
- puberty /
- bone age

[1]	屈茹楠, 范加龙, 刘慧, 张贺, 毛峻琴. 重组人粒细胞刺激因子致急性嗜酸性粒细胞肺炎的病例分析 . 药学实践与服务, 2022, 40(4): 364-367. doi: 10.12206/j.issn.1006-0111.202202029
[2]	邓子云, 沈祥国, 徐灿, 田泾. 注射用重组人Ⅱ型肿瘤坏死因子受体抗体融合蛋白治疗强直性脊柱炎疑致克罗恩病1例 . 药学实践与服务, 2020, 38(3): 286-288. doi: 10.12206/j.issn.1006-0111.201911045
[3]	蒋益忠, 夏天爽, 辛海量, 金玉娥, 蒋益萍, 薛黎明. 维生素K对成骨细胞骨形成和破骨细胞骨吸收的影响 . 药学实践与服务, 2020, 38(4): 340-345. doi: 10.12206/j.issn.1006-0111.202001077
[4]	叶盛英, 郭琪, 雷虹, 杨莹. 活骨丸质量标准研究 . 药学实践与服务, 2018, 36(2): 156-161. doi: 10.3969/j.issn.1006-0111.2018.02.012
[5]	刘国栋, 周丽, 张文静, 王卓. 粒细胞巨噬细胞刺激因子联合全肺灌洗对特发性肺泡蛋白沉积症的疗效和安全性 . 药学实践与服务, 2018, 36(2): 183-185. doi: 10.3969/j.issn.1006-0111.2018.02.019
[6]	王羽, 范宇平, 胡烨, 黄文强, 滕晓明. 联合激素治疗低促性腺激素性腺功能低下青春期发育迟滞 . 药学实践与服务, 2013, 31(5): 357-358,395. doi: 10.3969/j.issn.1006-0111.2013.05.010
[7]	张琪, 夏爱军. 重组人血管内皮抑制素联合化疗治疗非小细胞肺癌疗效的Meta分析 . 药学实践与服务, 2010, 28(6): 451-455.
[8]	李蔚, 白莉莉. 左氧氟沙星(来立信)致骨痛1例 . 药学实践与服务, 2006, (2): 98-98.
[9]	陈梅莉, 马友正. 噻嗪类药物对骨的影响 . 药学实践与服务, 2003, (1): 36-37.
[10]	唐冰, 陈燕, 尚北城. 重组人干扰素α-2b致脱发1例 . 药学实践与服务, 2003, (4): 213-213.
[11]	张榕红, 王红. 膝关节骨性关节炎应用中药熏洗疗法 . 药学实践与服务, 2001, (6): 329-329.
[12]	陆兵, 谢英华, 程度胜, 朱厚础. 重组人表皮生长因子凝胶剂的研制 . 药学实践与服务, 2001, (3): 143-145.
[13]	蒙诚跃, 梁自乾, 王润秀, 张立明, 李德绘, 覃桂萍. 应用人重组生长激素治疗大面积烧伤疗效的观察 . 药学实践与服务, 2001, (6): 326-327.
[14]	景利, 曾仁杰, 孙伟张, 刘清. 米托蒽醌缓释复合人工骨体外释放度考察 . 药学实践与服务, 1999, (5): 298-299.
[15]	李朴清, 陈爱华, 张纯, 黄春明. 骨蜡制剂处方的改进 . 药学实践与服务, 1999, (1): 61-61.
[16]	许芾, 龚文琴. 骨蜡制剂工艺的改进 . 药学实践与服务, 1997, (1): 28-29.
[17]	周建设, 史荣组. 生长激素临床应用进展 . 药学实践与服务, 1997, (3): 143-144,150.
[18]	赵小亭, 郭良耀, 王在田. 重组人促中性粒细胞集落刺激因子的临床疗效观察 . 药学实践与服务, 1995, (6): 330-332.
[19]	王皓, 宋赵军. 重组人GM-CSF临床应用研究近况 . 药学实践与服务, 1993, (3): 162-165.
[20]	刘月娥, 胡兴钰. 大剂量局部注射皮质激素引起溶骨性骨坏死 . 药学实践与服务, 1986, (4): 33-34.

点击查看大图

计量

文章访问数: 1984
HTML全文浏览量: 83
PDF下载量: 929
被引次数: 0

重组人生长激素治疗青春后期特发性矮小临床观察

浙江省湖州市妇幼保健院儿科, 浙江湖州313000

收稿日期: 2011-11-11
修回日期: 2011-12-08

关键词:

摘要: 目的探讨基因重组人生长激素(rhGH)对青春后期特发性矮小的促生长效应.方法 11例青春后期矮小患儿,按性别分为2组,A组,男5例,骨龄14～15岁,B组,女6例,骨龄12.5～13.5岁,每晚睡前皮下注射rhGH,剂量0.15 IU/(kg.d),疗程6个月.结果 2组患儿的身高分别由治疗前(148.6±2.6)cm、(139.6±2.9)cm增加到(153.6±2.1)cm、(143.8±2.5)cm,生长速率分别由治疗前(3.8±0.5)cm/年、

English Abstract

Effect of recombinant human growth hormone therapy on late puberty children with idiopathic short stature

Department of Peadiatrics, Maternal and Child Care Service Center of Huzhou, Huzhou 313000, China

Received Date: 2011-11-11
Rev Recd Date: 2011-12-08

Keywords:

Abstract: Objective To assess the efficacy of recombinant human growth hormone (rhGH) therapy in late puberty children with idiopathic short stature. Methods 11 children in late puberty with idiopathic short stature (ISS) were divided into 2 groups according to sex.A group consisted of 5 boys, B group was composed of 6 girls. Bone age (BA) of A group was (14～15) years, and BA of B group was (12.5～13.5) years.The enrolled children were treated with subcutaneous injection of rhGH (0.15 IU/kg·d) daily before sleep for six months,and the growth velocities (GV) and the predicted adult height (PAH) before and after treatment were compared. Results The mean height of A group and B group increased from (148.6±2.6) cm and (139.6±2.9) cm to (153.6±2.1) cm and (143.8±2.5) cm respectively. The growth velocity of A group and B group increased from (3.8±0.5) cm and (3.3±0.6) cm per year to (9.8±1.7) cm and (8.4±1.8) cm per year.PAH of A group and B group increased from (158.9±3.0) cm and (147.6±1.2) cm to (160.3±3.0) cm and (149.2±1.6) cm. There was a significant increase in rhGH therapy (all P<0.05), but no change in BA during the whole course of rhGH therapy. Conclusion rhGH was an effective and safe drug in promoring the growth in late puberty children with ISS.

金薇, 陈继男, 文革生, 高毅. 重组人生长激素治疗青春后期特发性矮小临床观察[J]. 药学实践与服务, 2012, 30(4): 293-295.

引用本文:

金薇, 陈继男, 文革生, 高毅. 重组人生长激素治疗青春后期特发性矮小临床观察[J]. 药学实践与服务, 2012, 30(4): 293-295.

Citation: